Balanced splicing at the Tat-specific HIV-1 3′ss A3 is critical for HIV-1 replication

被引:35
|
作者
Erkelenz, Steffen [1 ]
Hillebrand, Frank [1 ]
Widera, Marek [1 ]
Theiss, Stephan [2 ]
Fayyaz, Anaam [3 ]
Degrandi, Daniel [4 ,5 ]
Pfeffer, Klaus [5 ]
Schaal, Heiner [1 ,4 ]
机构
[1] Univ Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, D-40225 Dusseldorf, Germany
[3] Michigan State Univ, Plant Biol Lab, E Lansing, MI USA
[4] Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany
[5] Univ Dusseldorf, Hosp Hyg, D-40225 Dusseldorf, Germany
来源
RETROVIROLOGY | 2015年 / 12卷
关键词
HIV-1; Tat; Viral transcription; Alternative splicing; SR proteins; SRSF2; SRSF6; Splicing regulatory element; SRE; HEXplorer; IMMUNODEFICIENCY-VIRUS TYPE-1; HNRNP A/B PROTEINS; PRE-MESSENGER-RNA; INTRONIC G RUN; SR PROTEINS; GENE-EXPRESSION; NEUTRALIZING ANTIBODIES; SILENCER ELEMENT; REGULATORY ELEMENTS; EXON;
D O I
10.1186/s12977-015-0154-8
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The viral regulatory protein Tat is essential for establishing a productive transcription from the 5'-LTR promoter during the early phase of viral gene expression. Formation of the Tat-encoding mRNAs requires splicing at the viral 3'ss A3, which has previously been shown to be both negatively and positively regulated by the downstream splicing regulatory elements (SREs) ESS2p and ESE2/ESS2. However, using the novel RESCUE-type computational HEXplorer algorithm, we were recently able to identify another splicing enhancer (ESE5807-5838, henceforth referred to as ESEtat) located between ESS2p and ESE2/ESS2. Here we show that ESEtat has a great impact on viral tat-mRNA splicing and that it is fundamental for regulated 3'ss A3 usage. Results: Mutational inactivation or locked nucleic acid (LNA)-directed masking of the ESEtat sequence in the context of a replication-competent virus was associated with a failure (i) to activate viral 3'ss A3 and (ii) to accumulate Tat-encoding mRNA species. Consequently, due to insufficient amounts of Tat protein efficient viral replication was drastically impaired. RNA in vitro binding assays revealed SRSF2 and SRSF6 as candidate splicing factors acting through ESEtat and ESE2 for 3'ss A3 activation. This notion was supported by coexpression experiments, in which wild-type, but not ESEtat-negative provirus responded to higher levels of SRSF2 and SRSF6 proteins with higher levels of tat-mRNA splicing. Remarkably, we could also find that SRSF6 overexpression established an antiviral state within provirus-transfected cells, efficiently blocking virus particle production. For the anti-HIV-1 activity the arginine-serine (RS)-rich domain of the splicing factor was dispensable. Conclusions: Based on our results, we propose that splicing at 3'ss A3 is dependent on binding of the enhancing SR proteins SRSF2 and SRSF6 to the ESEtat and ESE2 sequence. Mutational inactivation or interference specifically with ESEtat activity by LNA-directed masking seem to account for an early stage defect in viral gene expression, probably by cutting off the supply line of Tat that HIV needs to efficiently transcribe its genome.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] HIV-1 tat intersects the SUMO pathway to regulate HIV-1 promoter activity
    McCartin, Ann Marie
    Kulkarni, Anurag
    Le Douce, Valentin
    Gautier, Virginie
    RETROVIROLOGY, 2016, 13
  • [32] The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies
    Rice, Andrew P.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (28) : 4098 - 4102
  • [33] A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication
    Massari, Serena
    Daelemans, Dirk
    Barreca, Maria Letizia
    Knezevich, Anna
    Sabatini, Stefano
    Cecchetti, Violetta
    Marcello, Alessandro
    Pannecouque, Christophe
    Tabarrini, Oriana
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (02) : 641 - 648
  • [34] EFFECT OF ANTIBODY TO HIV-1 TAT PROTEIN ON VIRAL REPLICATION IN-VITRO AND PROGRESSION OF HIV-1 DISEASE IN-VIVO
    FURLINI, MCRG
    VIGNOLI, M
    RAMAZZOTTI, E
    RODERIGO, G
    DEROSA, V
    ZAULI, G
    LOLLI, S
    CAPITANI, S
    LAPLACA, M
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 (04): : 408 - 416
  • [35] The Tat protein of HIV-1 induces galectin-3 expression
    Fogel, S
    Guittaut, M
    Legrand, A
    Monsigny, M
    Hébert, E
    GLYCOBIOLOGY, 1999, 9 (04) : 383 - 387
  • [36] ANTIBODY TO HIV-1 TAT PROTEIN INHIBITS THE REPLICATION OF VIRUS IN CULTURE
    STEINAA, L
    SORENSEN, AM
    NIELSEN, JO
    HANSEN, JES
    ARCHIVES OF VIROLOGY, 1994, 139 (3-4) : 263 - 271
  • [37] Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant
    Jin, Hongping
    Sun, Yifan
    Li, Dongsheng
    Lin, Min-Hsuan
    Lor, Mary
    Rustanti, Lina
    Harrich, David
    MBIO, 2019, 10 (04):
  • [38] Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme
    Jackson, WH
    Moscoso, H
    Nechtman, JF
    Galileo, DS
    Garver, FA
    Lanclos, KD
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 245 (01) : 81 - 84
  • [39] IL-10 INHIBITS HIV-1 REPLICATION AND IS INDUCED BY TAT
    MASOOD, R
    LUNARDIISKANDAR, Y
    MOUDGIL, T
    ZHANG, Y
    LAW, RE
    HUANG, CL
    PURI, RK
    LEVINE, AM
    GILL, PS
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (01) : 374 - 383
  • [40] Expression of HIV-1 integrase in CEM cells inhibits HIV-1 replication
    van Griensven, J
    Zhan, XJ
    Van Maele, B
    Pluymers, W
    Michiels, M
    De Clercq, E
    Cherepanov, P
    Debyser, Z
    JOURNAL OF GENE MEDICINE, 2004, 6 (03): : 268 - 277